Beam Therapeutics Inc. Operating Income
Beam Therapeutics Inc. (BEAM) reported Operating Income of -$126.55 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-04
- Beam Therapeutics Inc. operating income (loss) for the quarter ending 2026-06-30 was -$126.55M.
- Beam Therapeutics Inc. operating income (loss) for the quarter ending 2026-03-31 was -$107.22M.
- Beam Therapeutics Inc. operating income (loss) for the quarter ending 2025-12-31 was -$17.45M.
- Beam Therapeutics Inc. operating income (loss) for the quarter ending 2025-09-30 was -$126.81M.
- Beam Therapeutics Inc. operating income (loss) for fiscal 2025 was -$383.69M.
- Beam Therapeutics Inc. operating income (loss) for fiscal 2024 was -$415.57M.
- Beam Therapeutics Inc. operating income (loss) for fiscal 2023 was -$176.49M.
- Beam Therapeutics Inc. operating income (loss) for fiscal 2022 was -$338.48M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$126.55M 10-Q · filed 2026-08-04 | -$233.77M 10-Q · filed 2026-08-04 | -$251.21M derived: sum of 3 quarters · filed 2026-08-04 | -$378.02M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$107.22M 10-Q · filed 2026-05-07 | -$124.66M derived: sum of 2 quarters · filed 2026-05-07 | -$251.47M derived: sum of 3 quarters · filed 2026-05-07 | -$371.62M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$17.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$144.26M derived: sum of 2 quarters · filed 2026-02-24 | -$264.41M derived: sum of 3 quarters · filed 2026-08-04 | -$383.69M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$126.81M 10-Q · filed 2025-11-04 | -$246.96M derived: sum of 2 quarters · filed 2026-08-04 | -$366.25M 10-Q · filed 2025-11-04 | -$466.29M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$120.15M 10-Q · filed 2026-08-04 | -$239.44M 10-Q · filed 2026-08-04 | -$339.47M derived: sum of 3 quarters · filed 2026-08-04 | -$445.98M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$119.29M 10-Q · filed 2026-05-07 | -$219.32M derived: sum of 2 quarters · filed 2026-05-07 | -$325.83M derived: sum of 3 quarters · filed 2026-05-07 | -$430.72M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$100.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$206.54M derived: sum of 2 quarters · filed 2026-02-24 | -$311.44M derived: sum of 3 quarters · filed 2026-02-24 | -$415.57M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$106.50M 10-Q · filed 2025-11-04 | -$211.40M derived: sum of 2 quarters · filed 2025-11-04 | -$315.53M 10-Q · filed 2025-11-04 | -$182.67M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$104.89M 10-Q · filed 2025-08-05 | -$209.03M 10-Q · filed 2025-08-05 | -$76.17M derived: sum of 3 quarters · filed 2026-02-24 | -$184.44M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$104.13M 10-Q · filed 2025-05-06 | $28.73M derived: sum of 2 quarters · filed 2026-02-24 | -$79.54M derived: sum of 3 quarters · filed 2026-02-24 | -$181.69M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $132.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $24.59M derived: sum of 2 quarters · filed 2026-02-24 | -$77.56M derived: sum of 3 quarters · filed 2026-02-24 | -$176.49M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$108.27M 10-Q · filed 2024-11-05 | -$210.41M derived: sum of 2 quarters · filed 2024-11-05 | -$309.34M 10-Q · filed 2024-11-05 | -$398.33M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | -$102.15M 10-Q · filed 2024-08-06 | -$201.08M 10-Q · filed 2024-08-06 | -$290.06M derived: sum of 3 quarters · filed 2025-02-25 | -$381.36M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$98.93M 10-Q · filed 2024-05-07 | -$187.91M derived: sum of 2 quarters · filed 2025-02-25 | -$279.22M derived: sum of 3 quarters · filed 2025-02-25 | -$361.18M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | -$88.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$180.29M derived: sum of 2 quarters · filed 2025-02-25 | -$262.25M derived: sum of 3 quarters · filed 2025-02-25 | -$338.48M 10-K · filed 2025-02-25 |
| 2022-09-30 | -$91.30M 10-Q · filed 2023-11-08 | -$173.27M derived: sum of 2 quarters · filed 2023-11-08 | -$249.49M 10-Q · filed 2023-11-08 | -$312.98M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$81.97M 10-Q · filed 2023-08-08 | -$158.19M 10-Q · filed 2023-08-08 | -$221.68M derived: sum of 3 quarters · filed 2024-02-27 | -$291.31M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$76.22M 10-Q · filed 2023-05-10 | -$139.71M derived: sum of 2 quarters · filed 2024-02-27 | -$209.34M derived: sum of 3 quarters · filed 2024-02-27 | -$268.32M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$63.48M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$133.12M derived: sum of 2 quarters · filed 2024-02-27 | -$192.09M derived: sum of 3 quarters · filed 2024-02-27 | -$392.46M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$69.63M 10-Q · filed 2022-11-07 | -$128.61M derived: sum of 2 quarters · filed 2022-11-07 | -$328.98M 10-Q · filed 2022-11-07 | -$369.78M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$58.97M 10-Q · filed 2022-08-09 | -$259.35M 10-Q · filed 2022-08-09 | -$300.15M derived: sum of 3 quarters · filed 2023-02-28 | -$337.47M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$200.37M 10-Q · filed 2022-05-09 | -$241.17M derived: sum of 2 quarters · filed 2023-02-28 | -$278.49M derived: sum of 3 quarters · filed 2023-02-28 | -$304.78M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$40.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$78.12M derived: sum of 2 quarters · filed 2023-02-28 | -$104.41M derived: sum of 3 quarters · filed 2023-02-28 | -$132.76M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$37.32M 10-Q · filed 2021-11-08 | -$63.61M derived: sum of 2 quarters · filed 2021-11-08 | -$91.96M 10-Q · filed 2021-11-08 | -$118.33M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$26.29M 10-Q · filed 2021-08-10 | -$54.64M 10-Q · filed 2021-08-10 | -$81.01M derived: sum of 3 quarters · filed 2022-02-28 | -$99.03M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$28.36M 10-Q · filed 2021-05-11 | -$54.73M derived: sum of 2 quarters · filed 2022-02-28 | -$72.75M derived: sum of 3 quarters · filed 2022-02-28 | -$90.40M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$26.37M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$44.40M derived: sum of 2 quarters · filed 2022-02-28 | -$62.05M derived: sum of 3 quarters · filed 2022-02-28 | -$75.15M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$18.02M 10-Q · filed 2020-11-10 | -$35.67M derived: sum of 2 quarters · filed 2020-11-10 | -$48.78M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | -$17.65M 10-Q · filed 2020-08-12 | -$30.76M 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | -$13.11M 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |